| Eliticia E Vieyra, | |
|
20324 Veterans Dr Ste 104, Elkhorn, NE 68022-3552 | |
| (402) 933-5700 | |
| (402) 933-9998 |
| Full Name | Eliticia E Vieyra |
|---|---|
| Gender | Female |
| Speciality | Clinical Social Worker |
| Experience | 17 Years |
| Location | 20324 Veterans Dr Ste 104, Elkhorn, Nebraska |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518527951 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | 1612 (Nebraska) | Secondary |
| 1041C0700X | Social Worker - Clinical | 1672 (Nebraska) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Integrative Psychiatry Llc | 8325478126 | 4 |
News Archive
Softheon, Inc., a proven leader in health insurance marketplace integration and business operation, announced today that Health Republic Insurance Company has chosen the Marketplace Connector Cloud (MC2) as their software platform that will integrate and transition its comprehensive plan offerings for individuals and SHOP plans, both on and off Exchange, to the Federally Facilitated Marketplace.
A new study suggests joint complaints attributed to aromatase inhibitors (AI), popular breast cancer drugs, are not associated with inflammatory arthritis or autoimmune disease. Because of that, researchers say women who were primarily concerned about the threat of arthritis should be encouraged to continue taking the medication. The findings of the study will be presented Tuesday, Nov. 9 at the 74th Annual Scientific Meeting of the American College of Rheumatology in Atlanta, Georgia
Inverness Medical Innovations, Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today announced its financial results for the quarter ended September 30, 2009.
Results from a new study showed that coadministration of Zetia (ezetimibe) and fenofibrate significantly reduced LDL ("bad") cholesterol (LDL-C), non-high density lipoprotein cholesterol (non-HDL-C) and apo B1 in patients with mixed hyperlipidemia and high LDL cholesterol when compared to fenofibrate alone.
Bert Vogelstein, M.D., co-director of the Ludwig Center at Johns Hopkins and a Howard Hughes Medical Institute investigator has been awarded the Breakthrough Prize in Life Sciences. He was selected for his landmark work in cancer genomics and tumor suppressor genes.
› Verified 2 days ago
| Entity Name | Alegent Creighton Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033288923 PECOS PAC ID: 1850285255 Enrollment ID: O20040326000802 |
News Archive
Softheon, Inc., a proven leader in health insurance marketplace integration and business operation, announced today that Health Republic Insurance Company has chosen the Marketplace Connector Cloud (MC2) as their software platform that will integrate and transition its comprehensive plan offerings for individuals and SHOP plans, both on and off Exchange, to the Federally Facilitated Marketplace.
A new study suggests joint complaints attributed to aromatase inhibitors (AI), popular breast cancer drugs, are not associated with inflammatory arthritis or autoimmune disease. Because of that, researchers say women who were primarily concerned about the threat of arthritis should be encouraged to continue taking the medication. The findings of the study will be presented Tuesday, Nov. 9 at the 74th Annual Scientific Meeting of the American College of Rheumatology in Atlanta, Georgia
Inverness Medical Innovations, Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today announced its financial results for the quarter ended September 30, 2009.
Results from a new study showed that coadministration of Zetia (ezetimibe) and fenofibrate significantly reduced LDL ("bad") cholesterol (LDL-C), non-high density lipoprotein cholesterol (non-HDL-C) and apo B1 in patients with mixed hyperlipidemia and high LDL cholesterol when compared to fenofibrate alone.
Bert Vogelstein, M.D., co-director of the Ludwig Center at Johns Hopkins and a Howard Hughes Medical Institute investigator has been awarded the Breakthrough Prize in Life Sciences. He was selected for his landmark work in cancer genomics and tumor suppressor genes.
› Verified 2 days ago
| Entity Name | Integrative Psychiatry Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063051472 PECOS PAC ID: 8325478126 Enrollment ID: O20200419000017 |
News Archive
Softheon, Inc., a proven leader in health insurance marketplace integration and business operation, announced today that Health Republic Insurance Company has chosen the Marketplace Connector Cloud (MC2) as their software platform that will integrate and transition its comprehensive plan offerings for individuals and SHOP plans, both on and off Exchange, to the Federally Facilitated Marketplace.
A new study suggests joint complaints attributed to aromatase inhibitors (AI), popular breast cancer drugs, are not associated with inflammatory arthritis or autoimmune disease. Because of that, researchers say women who were primarily concerned about the threat of arthritis should be encouraged to continue taking the medication. The findings of the study will be presented Tuesday, Nov. 9 at the 74th Annual Scientific Meeting of the American College of Rheumatology in Atlanta, Georgia
Inverness Medical Innovations, Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today announced its financial results for the quarter ended September 30, 2009.
Results from a new study showed that coadministration of Zetia (ezetimibe) and fenofibrate significantly reduced LDL ("bad") cholesterol (LDL-C), non-high density lipoprotein cholesterol (non-HDL-C) and apo B1 in patients with mixed hyperlipidemia and high LDL cholesterol when compared to fenofibrate alone.
Bert Vogelstein, M.D., co-director of the Ludwig Center at Johns Hopkins and a Howard Hughes Medical Institute investigator has been awarded the Breakthrough Prize in Life Sciences. He was selected for his landmark work in cancer genomics and tumor suppressor genes.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Eliticia E Vieyra, 20324 Veterans Dr Ste 104, Elkhorn, NE 68022-3552 Ph: (402) 933-5700 | Eliticia E Vieyra, 20324 Veterans Dr Ste 104, Elkhorn, NE 68022-3552 Ph: (402) 933-5700 |
News Archive
Softheon, Inc., a proven leader in health insurance marketplace integration and business operation, announced today that Health Republic Insurance Company has chosen the Marketplace Connector Cloud (MC2) as their software platform that will integrate and transition its comprehensive plan offerings for individuals and SHOP plans, both on and off Exchange, to the Federally Facilitated Marketplace.
A new study suggests joint complaints attributed to aromatase inhibitors (AI), popular breast cancer drugs, are not associated with inflammatory arthritis or autoimmune disease. Because of that, researchers say women who were primarily concerned about the threat of arthritis should be encouraged to continue taking the medication. The findings of the study will be presented Tuesday, Nov. 9 at the 74th Annual Scientific Meeting of the American College of Rheumatology in Atlanta, Georgia
Inverness Medical Innovations, Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today announced its financial results for the quarter ended September 30, 2009.
Results from a new study showed that coadministration of Zetia (ezetimibe) and fenofibrate significantly reduced LDL ("bad") cholesterol (LDL-C), non-high density lipoprotein cholesterol (non-HDL-C) and apo B1 in patients with mixed hyperlipidemia and high LDL cholesterol when compared to fenofibrate alone.
Bert Vogelstein, M.D., co-director of the Ludwig Center at Johns Hopkins and a Howard Hughes Medical Institute investigator has been awarded the Breakthrough Prize in Life Sciences. He was selected for his landmark work in cancer genomics and tumor suppressor genes.
› Verified 2 days ago